Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth

Area of Science:

• Biomedical Engineering
• Oncology
• Nanotechnology

Background:

• High-grade serous ovarian cancer (HGSOC) is a deadly gynecologic malignancy with poorly understood molecular drivers.
• Gold nanoparticles (GNPs) possess inherent therapeutic properties that can be leveraged for cancer treatment.

Purpose of the Study:

• To identify a molecular axis promoting HGSOC growth by exploiting the self-therapeutic properties of GNPs.
• To assess the safety and efficacy of GNPs in preclinical models of HGSOC.
• To elucidate the molecular mechanisms underlying GNP-mediated inhibition of HGSOC growth.

Main Methods:

• Assessment of GNP biodistribution and toxicity via intravenous and intraperitoneal injection in single and repeated dosing regimens.
• Treatment of orthotopic patient-derived xenograft (PDX) and cell line-based human xenograft models of HGSOC with GNPs.
• Investigation of molecular mechanisms involving the insulin growth factor binding protein 2 (IGFBP2)/mTOR/PTEN axis.
• Combination therapy using GNPs and an mTOR dual-kinase inhibitor (PI-103).

Main Results:

• GNPs demonstrated no biochemical or histological toxicity to vital organs.
• GNP treatment robustly inhibited tumor growth in an orthotopic HGSOC PDX model.
• GNPs were found to downregulate IGFBP2 by disrupting its autoregulation via the IGFBP2/mTOR/PTEN axis.
• Combination therapy with GNPs and PI-103 showed similar efficacy to GNPs alone in inhibiting ovarian tumor growth.

Conclusions:

• GNPs can serve as a discovery tool to identify critical signaling axes in cancer.
• The IGFBP2/mTOR/PTEN axis is identified as a key driver of HGSOC progression.
• Exploiting this axis presents a promising therapeutic opportunity for improving outcomes in ovarian cancer patients.